Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy.
Anticoagulation
Bleeding
Clavien–Dindo classification
Complications
HoLEP
Transfusion
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
27
03
2020
accepted:
19
05
2020
pubmed:
4
6
2020
medline:
7
10
2021
entrez:
4
6
2020
Statut:
ppublish
Résumé
We evaluated efficacy and safety profile of patients with anticoagulation therapy (AT) undergoing holmium laser enucleation of the prostate (HoLEP). Within our prospective institutional database (11/2017 to 11/2019), we analyzed functional outcomes and 30-day complication rates of HoLEP patients according to Clavien-Dindo classification (CLD), stratified according to specific AT vs. no AT. Further analyses consisted of uni- and multivariate logistic regression models (LRM) predicting complications. Of 268 patients undergoing HoLEP, 104 (38.8%) received AT: 25.7% were treated with platelet aggregation inhibitors (PAI), 8.2% with new oral anticoagulants (NOAC) and 4.9% with AT-combinations or coumarins bridged with low molecular weight heparins (LMWH/combination). Patients receiving AT were significantly more comorbid (p < 0.01). Pre- and postoperative maximal flow rates, residual void urine and IPSS at 3 months after surgery were invariably improved after HoLEP for patients with/ without AT. Overall complication rate was 19.5% in patients with no AT vs. 26.1% vs. 27.3 vs. 46.2%, respectively, in patients with PAI, NOAC and LMWH/combination (p < 0.01). Major complications (CLD ≥ 3b) occurred in 6.1% of no AT patients vs. 4.3% vs. 4.5 vs. 0% in patients with PAI, NOAC and LMWH/combination, respectively (p < 0.01). In multivariate LRM, AT was not significantly associated with higher complication rates, whereas high ASA status (OR 2.2, p = 0.04), age (OR 1.04, p = 0.02) and bioptical or incidental prostate cancer (OR 2.5, p = 0.01) represented independent risk factors. Despite higher overall complication rates in AT patients, major complications were not more frequent in AT patients. HoLEP is safe and effective in anticoagulated patients.
Identifiants
pubmed: 32488362
doi: 10.1007/s00345-020-03272-2
pii: 10.1007/s00345-020-03272-2
pmc: PMC8124040
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1219-1226Références
Kim EH, Larson JA, Andriole GL (2016) Management of benign prostatic hyperplasia. Annu Rev Med 67:137–151
doi: 10.1146/annurev-med-063014-123902
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328
doi: 10.1016/S0302-2838(02)00354-8
DeWilde S, Carey IM, Emmas C, Richards N, Cook DG (2006) Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 92(8):1064–1070
doi: 10.1136/hrt.2005.069492
Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5(5):615–621
doi: 10.1161/CIRCOUTCOMES.112.967299
Sindet-Pedersen C, Pallisgaard JL, Staerk L, Berger JS, Lamberts M, Torp-Pedersen C et al (2017) Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism—a Danish nationwide cohort study. Sci Rep 7(1):3347
doi: 10.1038/s41598-017-03596-x
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109
doi: 10.1016/j.eururo.2014.12.038
Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64(6):623–625
doi: 10.1111/j.1464-410X.1989.tb05322.x
Michalak J, Tzou D, Funk J (2015) HoLEP: the gold standard for the surgical management of BPH in the 21(st) century. Am J Clin Exp Urol 3(1):36–42
pubmed: 26069886
pmcid: 4446381
Rivera M, Krambeck A, Lingeman J (2017) Holmium laser enucleation of the prostate in patients requiring anticoagulation. Curr Urol Rep 18(10):77
doi: 10.1007/s11934-017-0727-2
Suardi N, Gallina A, Salonia A, Briganti A, Deho F, Zanni G et al (2009) Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Curr Opin Urol 19(1):38–43
doi: 10.1097/MOU.0b013e32831a7008
Gilling PJ, Cass CB, Cresswell MD, Fraundorfer MR (1996) Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology 47(1):48–51
doi: 10.1016/S0090-4295(99)80381-1
Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175(4):1428–1432
doi: 10.1016/S0022-5347(05)00645-2
Bishop CV, Liddell H, Ischia J, Paul E, Appu S, Frydenberg M et al (2013) Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy. Curr Urol 7(1):28–33
doi: 10.1159/000343549
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Mitropoulos D, Artibani W, Biyani CS, Bjerggaard Jensen J, Roupret M, Truss M (2018) Validation of the Clavien–Dindo grading system in urology by the European Association of Urology guidelines ad hoc panel. Eur Urol Focus 4(4):608–613
doi: 10.1016/j.euf.2017.02.014
Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17(12):1185–1196
doi: 10.1080/14740338.2018.1546841
Payne RA (2016) The epidemiology of polypharmacy. Clin Med (Lond) 16(5):465–469
doi: 10.7861/clinmedicine.16-5-465
Becker B, Netsch C, Hansen J, Bohme A, Gross AJ, Zacharias M et al (2019) Perioperative safety in patient under oral anticoagulation during holmium laser enucleation of the prostate. J Endourol 33(3):219–224
doi: 10.1089/end.2018.0693
Zheng X, Peng L, Cao D, Han X, Xu H, Yang L et al (2019) Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis. Int Urol Nephrol 51(12):2127–2136
doi: 10.1007/s11255-019-02278-z
Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR (2003) A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 170(4 Pt 1):1270–1274
doi: 10.1097/01.ju.0000086948.55973.00
Li S, Zeng XT, Ruan XL, Weng H, Liu TZ, Wang X et al (2014) Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLoS ONE 9(7):e101615
doi: 10.1371/journal.pone.0101615
Kuntz RM, Ahyai S, Lehrich K, Fayad A (2004) Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol 172(3):1012–1016
doi: 10.1097/01.ju.0000136218.11998.9e
El Tayeb MM, Jacob JM, Bhojani N, Bammerlin E, Lingeman JE (2016) Holmium laser enucleation of the prostate in patients requiring anticoagulation. J Endourol 30(7):805–809
doi: 10.1089/end.2016.0070
Tyson MD, Lerner LB (2009) Safety of holmium laser enucleation of the prostate in anticoagulated patients. J Endourol 23(8):1343–1346
doi: 10.1089/end.2009.0013
Boeri L, Capogrosso P, Ventimiglia E, Fontana M, Sampogna G, Zanetti SP, et al. Clinical comparison of holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate in patients under either anticoagulation or antiplatelet therapy. Eur Urol Focus. 2019.
Sun I, Yoo S, Park J, Cho SY, Jeong H, Son H et al (2019) Quality of life after photo-selective vaporization and holmium-laser enucleation of the prostate: 5-year outcomes. Sci Rep 9(1):8261
doi: 10.1038/s41598-019-44686-2
Alkan I, Ozveri H, Akin Y, Ipekci T, Alican Y (2016) Holmium laser enucleation of the prostate: surgical, functional, and quality-of-life outcomes upon extended follow-up. Int Braz J Urol 42(2):293–301
doi: 10.1590/S1677-5538.IBJU.2014.0561